Protalix BioTherapeutics to Present at Investor Summit Virtual
Protalix BioTherapeutics (NYSE American:PLX), a biopharmaceutical company specializing in recombinant therapeutic proteins using its ProCellEx® plant cell-based protein expression system, has announced its participation in the upcoming Q3 Investor Summit Virtual.
The company's former Senior Vice President and CFO, Eyal Rubin, will deliver a presentation on September 16, 2025, at 10:30 AM EDT. The presentation will focus on the company's growth strategies and market opportunities, and will be accessible via webcast.
Protalix BioTherapeutics (NYSE American:PLX), azienda biofarmaceutica specializzata in proteine terapeutiche ricombinanti tramite il sistema di espressione proteica in cellule vegetali ProCellEx®, annuncia la propria partecipazione al prossimo Q3 Investor Summit Virtual.
L'ex Senior Vice President e CFO dell'azienda, Eyal Rubin, terrà una presentazione il 16 settembre 2025 alle 10:30 EDT. L'intervento verterà sulle strategie di crescita e le opportunità di mercato della società e sarà fruibile tramite webcast.
Protalix BioTherapeutics (NYSE American:PLX), una compañía biofarmacéutica especializada en proteínas terapéuticas recombinantes mediante su sistema de expresión en células vegetales ProCellEx®, ha anunciado su participación en el próximo Q3 Investor Summit Virtual.
El ex vicepresidente sénior y director financiero de la compañía, Eyal Rubin, ofrecerá una presentación el 16 de septiembre de 2025 a las 10:30 AM EDT. La charla se centrará en las estrategias de crecimiento y las oportunidades de mercado de la empresa, y podrá seguirse por webcast.
Protalix BioTherapeutics (NYSE American:PLX)는 ProCellEx® 식물 세포 기반 단백질 발현 시스템을 이용한 재조합 치료용 단백질을 전문으로 하는 바이오제약 기업으로, 다가오는 Q3 Investor Summit Virtual에 참여한다고 발표했습니다.
회사의 전 수석 부사장이자 최고재무책임자였던 Eyal Rubin이 2025년 9월 16일 오전 10시 30분(EDT)에 발표를 진행합니다. 발표에서는 회사의 성장 전략과 시장 기회에 대해 다루며, 웨비캐스트로 시청할 수 있습니다.
Protalix BioTherapeutics (NYSE American:PLX), une société biopharmaceutique spécialisée dans les protéines thérapeutiques recombinantes via son système d'expression ProCellEx® à base de cellules végétales, a annoncé sa participation au prochain Q3 Investor Summit Virtual.
L'ancien vice-président principal et directeur financier de la société, Eyal Rubin, présentera le 16 septembre 2025 à 10h30 (EDT). La présentation portera sur les stratégies de croissance et les opportunités de marché de l'entreprise et sera accessible en webcast.
Protalix BioTherapeutics (NYSE American:PLX), ein biopharmazeutisches Unternehmen, das sich auf rekombinante Therapeutika mithilfe des pflanzenzellenbasierten ProCellEx®-Expressionssystems spezialisiert hat, kündigt seine Teilnahme am bevorstehenden Q3 Investor Summit Virtual an.
Der ehemalige Senior Vice President und CFO des Unternehmens, Eyal Rubin, wird am 16. September 2025 um 10:30 Uhr EDT eine Präsentation halten. Diese wird sich auf die Wachstumsstrategien und Marktchancen des Unternehmens konzentrieren und per Webcast verfügbar sein.
- None.
- None.
CARMIEL, ISRAEL / ACCESS Newswire / September 11, 2025 / Protalix BioTherapeutics, Inc. (NYSE American:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today announced that Eyal Rubin, the Company's former Sr. Vice President and Chief Financial Officer, will present at the Investor Summit Virtual on September 16, 2025, updating investors about the Company's growth strategies and market opportunities.
Event Details
Event: Q3 Investor Summit
Presentation Date: September 16, 2025
Presentation Time: 10:30 a.m. Eastern Daylight Time (EDT)
Location: Webcast Link
About Protalix BioTherapeutics, Inc.
Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. It is the first company to gain U.S. Food and Drug Administration (FDA) approval of a protein produced through plant cell-based in suspension expression system. This unique expression system represents a new method for developing recombinant proteins in an industrial-scale manner. Protalix has licensed to Pfizer Inc. the worldwide development and commercialization rights to taliglucerase alfa for the treatment of Gaucher disease, Protalix's first product manufactured through ProCellEx, excluding in Brazil, where Protalix retains full rights. Protalix's second product, Elfabrio®, was approved by both the FDA and the European Medicines Agency in May 2023.
Protalix has partnered with Chiesi Farmaceutici S.p.A. for the global development and commercialization of Elfabrio. Protalix's development pipeline consists of proprietary versions of recombinant therapeutic proteins that target established pharmaceutical markets, including the following product candidates: PRX-115, a plant cell-expressed recombinant PEGylated uricase for the treatment of uncontrolled gout; PRX-119, a plant cell-expressed long acting DNase I for the treatment of NETs-related diseases; and others.
Conference Overview and Structure
The Investor Summit is an exclusive virtual event for investors specializing in small and microcap"/articles/market-capitalization-explained" title="Read: What Is Market Capitalization and How It Is Calculated" class="article-link" rel="noopener">microcap stocks. Attendees will:
Hear directly from company executives about key strategies and milestones
Learn from industry experts and thought leaders
Explore opportunities in the microcap"/articles/market-capitalization-explained" title="Read: What Is Market Capitalization and How It Is Calculated" class="article-link" rel="noopener">microcap market
This quarter's event emphasizes undervalued MicroCap"/articles/market-capitalization-explained" title="Read: What Is Market Capitalization and How It Is Calculated" class="article-link" rel="noopener">MicroCap companies with strong growth catalysts, providing investors with a unique platform for discovery and engagement.
Investor Registration:
Investors can register for free using the link below: https://investorsummitgroup.fillout.com/t/8CZGk3gSQbus
Sponsors:
ACCESS Newswire | PCG Advisory | QuoteMedia | AGP | MZ Group
Media Contact:
For more information, please visit https://investorsummitgroup.com/ or contact johnna-mae@investorsummitgroup.com
Investor Contact:
Mike Moyer, Managing Director
LifeSci Advisors
+1-617-308-4306
mmoyer@lifesciadvisors.com
SOURCE: Protalix BioTherapeutics, Inc.
View the original press release on ACCESS Newswire
FAQ
When is Protalix BioTherapeutics (PLX) presenting at the Q3 Investor Summit Virtual?
Who will be presenting for Protalix BioTherapeutics (PLX) at the Investor Summit?
What topics will be covered in Protalix BioTherapeutics' (PLX) Investor Summit presentation?
How can investors access Protalix BioTherapeutics' (PLX) Investor Summit presentation?
